<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275663</url>
  </required_header>
  <id_info>
    <org_study_id>KFMC-AML01</org_study_id>
    <nct_id>NCT02275663</nct_id>
  </id_info>
  <brief_title>Azacytidine Plus FLAG for Relapsed or Refractory AML</brief_title>
  <official_title>Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Fahad Medical City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Fahad Medical City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2 study is to test the efficacy of azacytidine given prior to
      fludarabine, cytarabine, and G-CSF for the treatment of relapsed or refractory acute myeloid
      leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>bone marrow blast &lt;5% with complete neutrophil (&gt;1000/ul) and platelets (&gt;100,000/ul) recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>leukemia free survival</measure>
    <time_frame>1-3 years</time_frame>
    <description>from time of complete remission to time of relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1-3 yeears</time_frame>
    <description>from date of enrolment to date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year leukemia free survival</measure>
    <time_frame>1 year</time_frame>
    <description>probability of leukemia free survival at one year of enrolment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Azacytidine plus FLAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1
G-CSF 5 mcg/kg subcut on days 0 to + 6
Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5
Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacytidine</intervention_name>
    <arm_group_label>Azacytidine plus FLAG</arm_group_label>
    <other_name>vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Azacytidine plus FLAG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Azacytidine plus FLAG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>G-CSF</description>
    <arm_group_label>Azacytidine plus FLAG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 16 to 60

          2. Patients with a diagnosis of relapse or refractory AML (≥ 20% blast in bone marrow).

          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          4. Patients must have preserved organ function as defined below:

               -  Creatinine ≤ 1.5 mg/dl

               -  Total bilirubin ≤ 1.5x upper limit of the normal

               -  Alanine aminotransferase (ALT) ≤ 2x upper limit of the normal

               -  Left ventricular ejection fraction (LVEF) ≥ 45%

        Exclusion Criteria:

          1. Patients with a diagnosis of acute promyelocytic leukemia (AML -M3)

          2. Pregnant women

          3. Patients previously treated with fludarabine are allowed to participate.

          4. Patients with Uncontrolled intercurrent illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ibraheem H Motabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Fahad Medical City</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ibraheem H Motabi, MD</last_name>
    <phone>+966 11 288 9999</phone>
    <phone_ext>11998</phone_ext>
    <email>imotabi@kfmc.med.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Humariya H Munshi</last_name>
    <phone>+966 11 288 9999</phone>
    <phone_ext>14029</phone_ext>
    <email>hmunshi@kfmc.med.sa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Fahad Medical City</name>
      <address>
        <city>Riyadh</city>
        <zip>11525</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibraheem Motabi, MD</last_name>
      <phone>+966112889999</phone>
      <phone_ext>11998</phone_ext>
      <email>imotabi@kfmc.med.sa</email>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>January 4, 2015</last_update_submitted>
  <last_update_submitted_qc>January 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Fahad Medical City</investigator_affiliation>
    <investigator_full_name>Ibraheem Motabi</investigator_full_name>
    <investigator_title>Consultant, Hematology and BMT</investigator_title>
  </responsible_party>
  <keyword>relapsed AML</keyword>
  <keyword>refractory AML</keyword>
  <keyword>azacytidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

